Hikma Pharmaceuticals Public annual r&d spending
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public R&D Spending Growth & History (HIK)
Hikma Pharmaceuticals Public's r&d spending was $151.0M for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $151.0M | $10.0M | +7.09% |
| 2024 | 2024-12-31 | $141.0M | −$8.0M | −5.37% |
| 2023 | 2023-12-31 | $149.0M | $5.0M | +3.47% |
| 2022 | 2022-12-31 | $144.0M | $1.0M | +0.70% |
| 2021 | 2021-12-31 | $143.0M | $6.0M | +4.38% |
| 2020 | 2020-12-31 | $137.0M | — | — |
Hikma Pharmaceuticals Public r&d spending trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's r&d spending increased from $137.0M to $151.0M, a change of $14.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
reported R&D expense
TickerStat standardizes research and development expense reported in company official filings, including the software-specific standardized R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...